Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study
- PMID: 21752435
- PMCID: PMC3336961
- DOI: 10.1016/j.ygyno.2011.06.022
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study
Abstract
Objective: Patients with persistent/recurrent epithelial ovarian cancer/primary peritoneal cancer (EOC/PPC) have limited treatment options. AKT and PI3K pathway activation is common in EOC/PPC, resulting in constitutive activation of downstream mTOR. The GOG conducted a phase II evaluation of efficacy and safety for the mTOR inhibitor, temsirolimus in EOC/PPC and explored circulating tumor cells (CTC) and AKT/mTOR/downstream tumor markers.
Methods: Eligible women with measurable, persistent/recurrent EOC/PPC who had received 1-3 prior regimens were treated with 25mg weekly IV temsirolimus until progression or intolerable toxicity. Primary endpoints were progression-free survival (PFS) ≥6-months, tumor response, and toxicity. CellSearch® system was used to examine CTC, and AKT/mTOR/downstream markers were evaluated by archival tumor immunohistochemistry. Kendall's tau-b correlation coefficient (r) and Cox regression modeling were used to explore marker associations with baseline characteristics and outcome.
Results: Sixty patients were enrolled in a two-stage sequential design. Of 54 eligible and evaluable patients, 24.1% (90% CI 14.9%-38.6%) had PFS ≥6 months (median 3.1 months), 9.3% (90% CI 3.7%-23.4%) experienced a partial response. Grade 3/4 adverse events included metabolic (8), gastrointestinal (8), pain (6), constitutional (5) and pulmonary (4). Suggested associations were between cyclin D1 and PFS ≥6 months, PFS or survival; positive CTC pre-treatment and lack of response; and high CTC expression of M30 and PFS ≥6 months/longer PFS.
Conclusions: Temsirolimus appears to have modest activity in persistent/recurrent EOC/PPC; however, PFS is just below that required to warrant inclusion in phase III studies in unselected patients. Cyclin D1 as a selection marker and CTC measures merit further study.
Trial registration: ClinicalTrials.gov NCT00429793.
Published by Elsevier Inc.
Conflict of interest statement
The authors wish to report that there are no conflicts of interest.
Figures



Similar articles
-
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.Gynecol Oncol. 2011 Jun 1;121(3):455-61. doi: 10.1016/j.ygyno.2011.02.013. Epub 2011 Mar 17. Gynecol Oncol. 2011. PMID: 21414654 Free PMC article. Clinical Trial.
-
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 2012 Oct;127(1):70-4. doi: 10.1016/j.ygyno.2012.06.009. Epub 2012 Jun 16. Gynecol Oncol. 2012. PMID: 22710075 Free PMC article. Clinical Trial.
-
A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.Gynecol Oncol. 2012 Jun;125(3):635-9. doi: 10.1016/j.ygyno.2012.03.023. Epub 2012 Mar 22. Gynecol Oncol. 2012. PMID: 22446624 Free PMC article. Clinical Trial.
-
The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis.Gynecol Oncol. 2021 Nov;163(2):433-444. doi: 10.1016/j.ygyno.2021.07.008. Epub 2021 Jul 10. Gynecol Oncol. 2021. PMID: 34253390
-
Current and future role of circulating tumor cells in patients with epithelial ovarian cancer.Eur J Surg Oncol. 2016 Dec;42(12):1772-1779. doi: 10.1016/j.ejso.2016.05.010. Epub 2016 May 25. Eur J Surg Oncol. 2016. PMID: 27265041 Review.
Cited by
-
Circulating tumour cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancers.Br J Cancer. 2012 Jul 24;107(3):448-54. doi: 10.1038/bjc.2012.276. Epub 2012 Jun 26. Br J Cancer. 2012. PMID: 22735905 Free PMC article.
-
Diagnosis and management of peritoneal metastases from ovarian cancer.Gastroenterol Res Pract. 2012;2012:541842. doi: 10.1155/2012/541842. Epub 2012 Jul 19. Gastroenterol Res Pract. 2012. PMID: 22888339 Free PMC article.
-
Identification of Key Genes and Pathways Involved in Circulating Tumor Cells in Colorectal Cancer.Anal Cell Pathol (Amst). 2022 Jan 27;2022:9943571. doi: 10.1155/2022/9943571. eCollection 2022. Anal Cell Pathol (Amst). 2022. PMID: 35127345 Free PMC article.
-
Inhibition of lysine-specific demethylase 1 prevents proliferation and mediates cisplatin sensitivity in ovarian cancer cells.Oncol Lett. 2018 Jun;15(6):9025-9032. doi: 10.3892/ol.2018.8511. Epub 2018 Apr 17. Oncol Lett. 2018. PMID: 29928330 Free PMC article.
-
Combined detection and subclass characteristics analysis of CTCs and CTECs by SE-iFISH in ovarian cancer.Chin J Cancer Res. 2021 Apr 30;33(2):256-270. doi: 10.21147/j.issn.1000-9604.2021.02.12. Chin J Cancer Res. 2021. PMID: 34158744 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
-
- Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol) 2005;17:399–341. - PubMed
-
- Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33:S3–S11. - PubMed
-
- Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–430. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous